The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | A deeper look at the genomics of multiple myeloma
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the need to better understand the genomics of multiple myeloma, and the benefit of observing disease progression from early stage monoclonal gammopathy of undetermined significance (MGUS) to symptomatic multiple myeloma. Dr Mohty also mentions the growing field of measurable residual disease (MRD) in myeloma, and that these fascinating topics will all be covered at this year’s COMy congress in Paris, France.
